Finding effective treatments and, ultimately, a cure for fragile X syndrome, the most common inherited cause of autism.
The main batch of 2018 grant applications arrived on February 1 and are now under review. FRAXA funds biomedical research aimed at finding specific treatments and ultimately a cure for fragile X syndrome.
Our top priority this year is clinical trials. We fund fragile X clinical trials of available drugs and investigational new drugs. We also support studies of biomarkers and other outcome measures that will enable, improve and streamline clinical trials.
Applications for clinical trials are accepted anytime throughout the year.
Fragile X syndrome is the most common inherited cause of autism and intellectual disabilities. It affects 1 in 4000 boys and 1 in 6000 girls of all races worldwide.
Fragile X occurs when a single gene shuts down. Our children lack one protein vital for normal brain function.
FRAXA Research Foundation is committed to finding effective treatments and, ultimately, a cure for fragile X syndrome. Three Nobel Laureates and other top-notch scientists make up our Scientific Advisory Board. FRAXA has funded over $26,000,000 in research worldwide; hundreds of teams are in their labs right now, testing, seeking, discovering.
Be a Friend of FRAXA
Friends of FRAXA are parents, grandparents, researchers, sisters, brothers, teachers. Meet our families – hear their stories. We welcome you as a Friend of FRAXA.
Treatment approaches are in the pipeline and clinical trials are underway. Join our community and keep up with the latest exciting advances.